Rather than being designed by chemists, this class of pharmaceuticals is produced by living cells. Here’s where they come from and how they work.
Articles on Pharmaceuticals
Displaying 161 - 180 of 262 articles
3D bioprinting of living cells and materials may contribute to faster and cheaper ways to create effective new drugs - and even reduce animal testing.
The state of Ohio filed a lawsuit against opioid manufacturers. Will their legal arguments hold up in court – and what will it mean for other cities and states going after big pharma?
Canada is the only nation with a broad public health system lacking universal coverage for pharmaceuticals. Despite fears that pharmacare would be too costly, it could end up saving Canadians money.
A push towards prescribing generic medications rather than their branded equivalents, as flagged in the budget, may have benefits beyond simple cost savings.
In many trials, patients have been told they’re getting the sugar pill. They still got better.
Wider availability of the cystic fibrosis drug Kalydeco since May 1, 2017 means younger patients can now access it.
Herbal remedies can be dangerous, but so can drugs approved by the FDA.
The newer drugs for hepatitis C might mean fewer people are diagnosed with liver cancer.
A pirated movie won’t kill you, but a counterfeit blood-thinner might. Australia needs stronger laws and tougher enforcement to counter fake drugs.
Alternative facts owe more to Aldous Huxley’s Brave New World than Orwell’s 1984.
The Social Medwork is a website that promises patients legal access to medicines from overseas. How does it work? What are the risks? And why are patients turning to it to access the drugs they need?
Antipsychotic medications for delirium don’t work and could harm, a new study shows. So what options are left?
Classing e-cigarettes as quit smoking aids could help rebrand the tobacco industry as a legitimate player in health policy. Here’s why we should be concerned.
Why US$790m is not enough to win the war against antibiotic resistance.
With the right investment, an open source drug discovery system might compete with the traditional pharmaceutical industry to deliver the drugs we need.
Just like humans, corals live with myriad microscopic organisms. We are just starting to understand this unseen world.
Why drug maker Mylan’s decision to introduce a half-price version of its EpiPen could be more than a publicity stunt.
Today, there are more than 20 cryptomarkets selling illicit drugs, or more than 55 if single-vendor markets are included.
A tin pot dictator plunders billions from his blighted nation’s treasury. Sensing he’ll soon be exiled, amid public relations fanfare, he offers ill-gotten millions to a local university for a new school…
Top contributors
-
Professor of Pharmaceutical Chemistry, Macquarie University
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Director and Taylor Family Chair, Centre for the Business & Economics of Health, The University of Queensland
-
Lecturer Pharmacy Practice, University of Sydney
-
Conjoint Clinical Associate Professor, Deakin University School of Medicine and Specialist Pain Medicine Physician, Deakin University
-
Pharmacist and PhD Candidate, University of Sydney
-
Professor of Bioethics, Macquarie University
-
Assistant Professor of Resource Economics, UMass Amherst
-
Professor of Trade Law and Taxation, Queensland University of Technology
-
Senior Research Manager, University of Sydney and Honorary Assistant Professor, Bond University
-
PhD Candidate, Swinburne University of Technology
-
Professor in Pharmaceutical Policy, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Senior Lecturer, Pharmacy, Aston University
-
Professor of Economics, Loughborough University